OncoMed Pharmaceuticals, Inc. (OMED) was a big mover last session, as its shares rose over 5% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend for the company since Aug 28, as the stock is now down above 16%.
In the last 30-day frame, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
OncoMed Pharmaceuticals currently has a Zacks Rank #5 (Strong Sell) while its Earnings ESP is 0.00%.
Better-ranked med-biomed gene stocks include Cambrex Corp. (CBM), China Biologic Products, Inc. (CBPO) and Gilead Sciences Inc. (GILD). While Cambrex and Gilead Sciences sport a Zacks Rank #1 (Strong Buy), China Biologic carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment